Indication
Tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
Medicine details
- Medicine name:
- epcoritamab (Tepkinly)
- SMC ID:
- SMC2881
- Pharmaceutical company
- AbbVie Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- 07 September 2026
- SMC meeting date:
- 04 August 2026
- Patient group submission deadline:
- 01 June 2026